Ones To Watch News
Refine Search
Biotechnology
Under pressure from activist Elliott to up its performance, UK pharma major GlaxoSmithKline on Friday revealed it has entered into a strategic global collaboration with USA-based biotech firm Alector to develop potential new drugs for Parkinson’s and Alzheimer’s disease. 3 July 2021
Biotechnology
French ophthalmics-focussed biotech Nicox has presented results from the Dolomites Phase II clinical trial showing that NCX 470, a novel nitric oxide (NO)-donating prostaglandin analog (PGA), produced significantly greater intraocular pressure (IOP) lowering effects in glaucoma patients compared with the current standard of care, latanoprost. 1 July 2021
Biotechnology
Austria-based rare diseases specialist AOP Orphan Pharmaceuticals announced its latest analysis on Besremi (ropeginterferon alfa-2b) in patients with Polycythemia Vera (PV), a rare blood cancer, from its CONTINUATION-PV study presented at the European Hematology Association (EHA) 2021 meeting by Professor Jean-Jacques Kiladjian from the Saint-Louis Hospital & Université de Paris in France. 1 July 2021
Biotechnology
UK and USA-based clinical-stage gene therapy specialist Orchard Therapeutics as entered into a strategic collaboration with Dutch firm Pharming Group to research, develop, manufacture and commercialize OTL-105. 1 July 2021
Pharmaceutical
Adding to a string of distribution deals, UK specialty pharma firm Diurnal Group (AIM: DNL) says it has extended its distribution arrangements with Er-Kim. 29 June 2021
Biotechnology
Colorado, USA-based SomaLogic yesterday said it is adding to its list of collaborative agreements with Danish diabetes care giant Novo Nordisk. 29 June 2021
Biotechnology
The Food and Drug Administration’s Endocrinologic and Metabolic Drugs Advisory Committee recently voted in favor of USA-based Provention Bio’s teplizumab by 10 yes to 7 no, on the question: "Does the information provided in the background documents and presentations by the Applicant and FDA show that the benefits of teplizumab outweigh the risks in support of approval to delay clinical type 1 diabetes mellitus?" 29 June 2021
Biotechnology
Shares of antibiotic and immuno-oncology specialist Polyphor plummeted nearly 70% to 2.40 Swiss francs after it reported the failure of its remaining investigational asset, balixafortide, to meet late-stage trial goal. 28 June 2021
Biotechnology
US clinical-stage biotech Pieris Pharmaceuticals today announced the development of PRS-220, an oral inhaled anticalin protein targeting connective tissue growth factor (CTGF), also known as CCN2, for the treatment of idiopathic pulmonary fibrosis (IPF). 25 June 2021
Biotechnology
US biotech Fulcrum Therapeutics today announced results from the company’s Phase IIb trial, ReDUX4, in people with facioscapulohumeral muscular dystrophy (FSHD). 24 June 2021
Pharmaceutical
As in other industries, the rise of the special purpose acquisition company (SPAC) as a means to going public is becoming more evident in pharma and biotech. 23 June 2021
Biotechnology
Iksuda Therapeutics, a privately-held UK-based developer of antibody drug conjugates (ADCs) with raised therapeutic index, has expanded its research collaboration and license agreement with Korean biotech LegoChem Biosciences. 22 June 2021
Biotechnology
Israeli drug developer RedHill Biopharma saw its shares edge up nearly 2% to $7.10 in early US trading, as the company released positive Phase II safety and efficacy data for oral Yeliva (opaganib, ABC294640) in hospitalized patients with COVID-19 pneumonia at the World Microbe Forum (WMF) 2021. 21 June 2021
Pharmaceutical
Privately-held Italian drugmaker Chiesi is releasing additional batches of Clenil Modulite (beclomethasone) for all strengths (50/100/200/250mcg) into the UK supply chain. 21 June 2021
Biotechnology
Having spiked 95% the day before the anticipated positive US regulatory decision on its rare disease treatment arimoclomol, Danish biopharma company Orphazyme fell sharply on Friday (June 18). 21 June 2021
Biotechnology
FibroGen and fellow USA-based HiFiBiO Therapeutics, a private, multinational clinical-stage biotherapeutics company with expertise in immune modulation and single cell science, have announced a partnership covering three HiFiBiO programs. 18 June 2021
Biotechnology
Gilead Sciences’ subsidiary has announced a strategic partnership with privately held US biotech Shoreline Biosciences to develop novel cell therapies across a variety of cancer targets. 18 June 2021
Pharmaceutical
UK drug developer Redx Pharma’s shares were up 6% at 62.00 pence by mid-morning, after it, announced that a milestone payment from AstraZeneca has been triggered as a result of progress in the development of RXC006, a pre-clinical porcupine inhibitor, targeting fibrotic diseases including idiopathic pulmonary fibrosis (IPF). 17 June 2021
Pharmaceutical
Ireland-incorporated Avadel Pharmaceuticals has announced new post hoc analyses of data from the completed pivotal Phase III REST-ON clinical trial of FT218, at SLEEP 2021. 16 June 2021
Pharmaceutical
Getting celiac disease (CD) diagnosed can be a long and difficult path for patients, and with no effective treatments available, the outcome is often a burdensome impact on quality of life. 15 June 2021
Biotechnology
Epitopea, a UK and Canada-based cancer immunotherapeutics company, has partnered with nucleic acid delivery specialist Genevant Sciences to develop new RNA-based therapies targeting proprietary tumor antigens. 20 December 2024
Pharmaceutical
US biotech Assembly Biosciences has announced an equity investment of $20.1 million by Gilead Sciences to purchase additional common stock in the company and an amendment to their collaboration to advance the research and development of novel antiviral therapies with $10 million in accelerated funding. 20 December 2024
Pharmaceutical
Privately-held Xcovery Holdings, an oncology-focused pharma company, has announced that the US Food and Drug Administration (FDA) has approved Ensacove (ensartinib) for the treatment of patients with anaplastic lymphoma kinase (ALK)-positive locally advanced or metastatic non-small cell lung cancer (NSCLC). 19 December 2024
Biotechnology
Privately-held biotech Ottimo Pharma today announces the completion of a Series A financing round of over $140 million. 19 December 2024
Biotechnology
Safi Biotherapeutics, a specialist in stem-cell derived red blood cell products, has received Rare Pediatric Disease designation and Orphan Drug designation from the US regulator. 19 December 2024
Biotechnology
BioAge Labs today announced a multi-year research collaboration with Swiss pharma giant Novartis, with the news pushing the US biotech’s shares up 6.1% to $4.35 by early afternoon. 18 December 2024
Pharmaceutical
Marking its second deal this month alone, Novo Nordisk has entered into a multi-year collaboration with Massachusetts, USA-based Photys Therapeutics to develop novel proximity-based therapeutics for a cardiometabolic disease target. 18 December 2024
Biotechnology
Cara Therapeutics and Tvardi Therapeutics have announced a definitive agreement to merge, creating a new entity under the Tvardi name. 18 December 2024
Pharmaceutical
SiteOne Therapeutics has announced the completion of a $100 million series C financing, led by Novo Holdings, with participation from OrbiMed, Wellington Management, Mission BioCapital, and others. 18 December 2024
Biotechnology
Flagship Pioneering-founded genome engineering biotech Tessera Therapeutics today announced an investment of up to $50 million from the Bill & Melinda Gates Foundation to develop curative, globally accessible in vivo genetic therapies for sickle cell disease. 18 December 2024
Biotechnology
San Francisco-based Indapta Therapeutics, a privately held start-up developing next-generation cell therapies, has raised $22.5 million in a new financing round. The firm raised over $50 million in series A funding in 2022. 18 December 2024
Biotechnology
French CNS specialist Theranexus saw its shares leap more than 34% to 0.65 euros as it revealed a license and supply agreement with Exeltis to commercialize TX01, its novel formulation of a compound already approved in the indication for the treatment of rare neurological diseases. 18 December 2024
Biotechnology
Shares in US biopharma Viridian Therapeutics shot up by 21% on Monday. 17 December 2024
Biotechnology
US antivirals giant Gilead Sciences today revealed it has entered into a strategic collaboration to discover and develop novel, small molecule therapies across multiple targets with Californian biotech Terray Therapeutics. 17 December 2024
Pharmaceutical
Swedish biotech company Inify Laboratories has raised approximately 135 million kroner ($12.3 million) through a private placement, supporting a planned expansion into the UK. 16 December 2024
Biotechnology
Dewpoint Therapeutics and ConcertAI have announced the first phase of their translational oncology partnership, aligned around the former company's latest drug candidate, DPTX3186. 16 December 2024
Biotechnology
Bicycle Therapeutics, a UK-headquartered pharma company developing a new class of therapeutics based on its proprietary bicyclic peptide technology, closed a third lower on Friday. 16 December 2024
Biotechnology
In a filing with the US financial regulator, German mRNA specialist BioNTech has noted the lifting of a partial clinical hold on its PRESERVE-003 trial. 16 December 2024
Biotechnology
VectorY Therapeutics, a Netherlands-based biotech focused on neurodegenerative diseases, has appointed Jim Scibetta as chief executive officer. 16 December 2024
Biotechnology
Sino-American biotech BeiGene has announced it has entered into a global licensing agreement with China’s CSPC Zhongqi Pharmaceutical Technology for SYH2039, a novel methionine adenosyltransferase 2A (MAT2A)-inhibitor being explored for solid tumors. 13 December 2024
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Today's issue
Company Spotlight
A US biotech company dedicated to creating oral drugs with an emphasis on indications in virology and immunology.
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze